Impact of treatment with rosuvastatin and atorvastatin on cardiovascular outcomes: evidence from the Archimedes-simulated clinical trials

References

• WHOGlobal Status Report on Noncommunicable Diseases 20102011 Available from: http://whqlibdoc.who.int/publications/2011/9789240686458_eng.pdf
   Google Scholar
• BaigentCKeechAKearneyPMCholesterol Treatment Trialists’ (CTT) CollaboratorsEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet200536694931267127816214597
   PubMed Web of Science ®Google Scholar
• ReinerZCatapanoALDe BackerGEuropean Association for Cardiovascular Prevention and RehabilitationESC/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS)Eur Heart J201132141769181821712404
   PubMed Web of Science ®Google Scholar
• PerkJDe BackerGGohlkeHEuropean guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)Eur Heart J201233131635170122555213
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) CollaborationBaigentCBlackwellLEfficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trialsLancet201037697531670168121067804
   PubMed Web of Science ®Google Scholar
• LaccettiRPotaAStrangesSEvidence on the prevalence and geographic distribution of major cardiovascular risk factors in ItalyPublic Health Nutr201216230531522647342
   PubMed Web of Science ®Google Scholar
• GrassiGArenareFDell’oroRPrevalence of cardiovascular risk factors in an unselected Italian population. Results of the Cardiolab Project 2004–2008Acta Cardiol200964677177820128154
   PubMed Web of Science ®Google Scholar
• Gomez-HuelgasRMancera-RomeroJBernal-LopezMRPrevalence of cardiovascular risk factors in an urban adult population from southern Spain. IMAP studyInt J Clin Pract2011651354021192342
   PubMed Web of Science ®Google Scholar
• GabrielRAlonsoMSeguraAERICE Cooperative GroupPrevalence, geographic distribution and geographic variability of major cardiovascular risk factors in Spain. Pooled analysis of data from population-based epidemiological studies: the ERICE studyRev Esp Cardiol200861101030104018817679
   PubMed Web of Science ®Google Scholar
• FirmannMMarques-VidalPPaccaudFPrevalence, treatment and control of dyslipidaemia in Switzerland: still a long way to goEur J Cardiovasc Prev Rehabil201017668268720700055
   PubMedGoogle Scholar
• Guallar-CastillónPGil-MonteroMLeón-MuñozLMMagnitude and management of hypercholesterolemia in the adult population of Spain, 2008–2010: the ENRICA studyRev Esp Cardiol (Engl ED)201265655155822483404
   PubMed Web of Science ®Google Scholar
• StoneNJRobinsonJLichtensteinAH2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American heart association task force on practice guidelinesCirculation201412925 Suppl 2S1S4524222016
   PubMed Web of Science ®Google Scholar
• CannonCPSteinbergBAMurphySAMegaJLBraunwaldEMeta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapyJ Am Coll Cardiol200648343844516875966
   PubMed Web of Science ®Google Scholar
• CannonCPBraunwaldEMcCabeCHPravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 InvestigatorsIntensive versus moderate lipid lowering with statins after acute coronary syndromesN Engl J Med2004350151495150415007110
   PubMed Web of Science ®Google Scholar
• LaRosaJCGrundySMWatersDDTreating to New Targets (TNT) InvestigatorsIntensive lipid lowering with atorvastatin in patients with stable coronary diseaseN Engl J Med2005352141425143515755765
   PubMed Web of Science ®Google Scholar
• de LemosJABlazingMAWiviottSDInvestigatorsEarly intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trialJAMA2004292111307131615337732
   PubMed Web of Science ®Google Scholar
• PedersenTRFaergemanOKasteleinJJIncremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study GroupHigh-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trialJAMA2005294192437244516287954
   PubMed Web of Science ®Google Scholar
• ColivicchiFTubaroMSantiniMClinical implications of switching from intensive to moderate statin therapy after acute coronary syndromesInt J Cardiol20111521566020674999
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education ProgramThird report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final reportCirculation2002106253143342112485966
   PubMed Web of Science ®Google Scholar
• LuvaiAMbagayaWHallASBarthJHRosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular diseaseClin Med Insights Cardiol20126173322442638
   PubMedGoogle Scholar
• RidkerPMRosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trialCirculation2003108192292229714609996
   PubMed Web of Science ®Google Scholar
• RidkerPMDanielsonEFonsecaFAJUPITER Study GroupRosuvastatin to prevent vascular events in men and women with elevated C-reactive proteinN Engl J Med2008359212195220718997196
   PubMed Web of Science ®Google Scholar
• SeverPSDahlöfBPoulterNRASCOT investigatorsPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial–lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trialLancet200336193641149115812686036
   PubMed Web of Science ®Google Scholar
• WatersDDGuytonJRHerringtonDMMcGowanMPWengerNKShearCTreating to new targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?Am J Cardiol200493215415814715339
   PubMed Web of Science ®Google Scholar
• SchwartzGGOlssonAGEzekowitzMDMyocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study InvestigatorsEffects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trialJAMA2001285131711171811277825
   PubMed Web of Science ®Google Scholar
• GibsonCMPrideYBHochbergCPSloanSSabatineMSCannonCPEffect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: a PROVE IT-TIMI 22 (pravastatin or ator-vastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22) substudyJ Am Coll Cardiol200954242290229519958964
   PubMed Web of Science ®Google Scholar
• JonesPHDavidsonMHSteinEASTELLAR Study GroupComparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)Am J Cardiol200392215216012860216
   PubMed Web of Science ®Google Scholar
• ClearfieldMBAmerenaJBassandJPComparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – prospective study to evaluate the use of low doses of the statins atorvastatin and rosuvastatin (PULSAR)Trials200673517184550
   PubMed Web of Science ®Google Scholar
• NichollsSJBallantyneCMBarterPJEffect of two intensive statin regimens on progression of coronary diseaseN Engl J Med2011365222078208722085316
   PubMed Web of Science ®Google Scholar
• SchlessingerLEddyDMArchimedes: a new model for simulating health care systems – the mathematical formulationJ Biomed Inform2002351375012415725
   PubMed Web of Science ®Google Scholar
• EddyDMSchlessingerLArchimedes: a trial-validated model of diabetesDiabetes Care200326113093310114578245
   PubMed Web of Science ®Google Scholar
• MH4MGComputer modeling of diabetes and its complications: a report on the fourth Mount Hood challenge meetingDiabetes Care20073061638164617526823
   PubMed Web of Science ®Google Scholar
• SchlessingerLEddyDMA Predictive Validation of the CARDS Trial2011 Available from: https://archimedesmodel.com/tech-reports
   Google Scholar
• EddyDMCohenMDShumKDziubaJValidation Methodology and Results: ARCHeS Simulator 2.52013 Available from: https://archimedesmodel.com/tech-reports
   Google Scholar
• SchuetzCAAlperinPGudaSA standardized vascular disease health check in europe: a cost-effectiveness analysisPLoS One201387e6645423869204
   PubMed Web of Science ®Google Scholar
• SamuelSPeskinBArondekarBEstimating health and economic benefits from using prescription omega-3 fatty acids in patients with severe hypertriglyceridemiaAm J Cardiol2011108569169721840433
   PubMed Web of Science ®Google Scholar
• Noah-VanhouckeJGreenLEDinhTAAlperinPSmithRACost-effectiveness of chemoprevention of breast cancer using tamoxifen in a postmenopausal US populationCancer2011117153322333121404271
   PubMed Web of Science ®Google Scholar
• PeskinBRShcheprovAVBoyeKSBruceSMaggsDGGaeblerJACardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs traditional therapies for type 2 diabetes: a simulation analysisDiabetes Obes Metab2011131092192721624032
   PubMed Web of Science ®Google Scholar
• CDCNational Health and Nutrition Examination Survey Data 1999–20082014 Available from: http://www.cdc.gov/nchs/nhanes.htm
   Google Scholar
• Diabetes Prevention ProgramStrategies to identify adults at high risk for type 2 diabetes: the diabetes prevention programDiabetes Care200528113814415616247
   PubMed Web of Science ®Google Scholar
• ColhounHMBetteridgeDJDurringtonPNCARDS investigatorsPrimary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trialLancet2004364943568569615325833
   PubMed Web of Science ®Google Scholar
• SchuetzCAvan HerickAAlperinPPeskinBHsiaJGandhiSComparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes modelJ Med Econ20121561118112922712873
   PubMedGoogle Scholar
• SchuetzAvan HerickAAlperinPPeskinBHsiaJGandhiSComparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes modelValue Health2011143A36
   Web of Science ®Google Scholar
• van HerickASchuetzCAAlperinPBullanoMFBaluSGandhiSThe impact of initial statin treatment decisions on cardiovascular outcomes in clinical care settings: estimates using the Archimedes modelClinicoecon Outcomes Res2012433734723180970
   PubMedGoogle Scholar
• FolseHSternhufvudCAndy SchuetzCRengarajanBGandhiSImpact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular eventsClin Ther2014361586924417785
   PubMed Web of Science ®Google Scholar
• RobinsonJGSmithBMaheshwariNSchrottHPleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysisJ Am Coll Cardiol200546101855186216286171
   PubMed Web of Science ®Google Scholar
• D’AgostinoRBSrVasanRSPencinaMJGeneral cardiovascular risk profile for use in primary care: the Framingham heart studyCirculation2008117674375318212285
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRSeventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressureHypertension20034261206125214656957
   PubMed Web of Science ®Google Scholar
• NathanDMBuseJBDavidsonMBManagement of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American diabetes association and the European association for the study of diabetesDiabetes Care200831117317518165348
   PubMed Web of Science ®Google Scholar
• WatersDDBrotonsCChiangCWLipid Treatment Assessment Project 2 InvestigatorsLipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goalsCirculation20091201283419546386
   PubMed Web of Science ®Google Scholar
• EddyDMSchlessingerLValidation of the archimedes diabetes modelDiabetes Care200326113102311014578246
   PubMed Web of Science ®Google Scholar
• ReinerZDe BacquerDKotsevaKPruggerCDe BackerGWoodDTreatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III surveyAtherosclerosis2013231230030724267243
   PubMed Web of Science ®Google Scholar
• VanuzzoDPilottoLAmbrosioGBEUROASPIRE Study GroupPotential for cholesterol lowering in secondary prevention of coronary heart disease in Europe: findings from EUROASPIRE study. European action on secondary prevention through intervention to reduce eventsAtherosclerosis2000153250551711164441
   PubMed Web of Science ®Google Scholar
• HermansMPCastro CabezasMStrandbergTCentralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countriesCurr Med Res Opin201026244545420001658
   PubMed Web of Science ®Google Scholar
• Perrone-FilardiPPoliAAmbrosioGProtoCChiminiCChiarielloMImplementation of cardiovascular secondary prevention guidelines in clinical practice: a nationwide survey in ItalyNutr Metab Cardiovasc Dis201222214915320875948
   PubMed Web of Science ®Google Scholar
• HobbsFDErhardtLAcceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the reassessing European attitudes about cardiovascular treatment (REACT) surveyFam Pract200219659660412429661
   PubMed Web of Science ®Google Scholar
• DallongevilleJBanegasJRTubachFEURIKA InvestigatorsSurvey of physicians’ practices in the control of cardiovascular risk factors: the EURIKA studyEur J Cardiovasc Prev Rehabil2011193541550
   Google Scholar
• SvilaasARisbergKThoresenMOseLLipid treatment goals achieved in patients treated with statin drugs in Norwegian general practiceAm J Cardiol2000861112501253A611090801
   PubMed Web of Science ®Google Scholar
• RuofJKleinGMarzWWollschlagerHNeissAWehlingMLipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patternsPrev Med2002351485312079440
   PubMed Web of Science ®Google Scholar
• AthyrosVGPapageorgiouAAMercourisBRTreatment with atorvastatin to the national cholesterol educational program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek atorvastatin and coronary-heart-disease evaluation (GREACE) studyCurr Med Res Opin200218422022812201623
   PubMed Web of Science ®Google Scholar
• van DamMvan WissenSKasteleinJJDeclaring war on undertreatment: rationale for an aggressive approach to lowering cholesterolJ Cardiovasc Risk200292899512006916
   PubMedGoogle Scholar
• WilleyVJBullanoMFShoetanNNGandhiSKTherapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatinCurr Med Res Opin201026112112819916706
   PubMed Web of Science ®Google Scholar
• SimpsonRJJrTunceliKRameyDRTreatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care settingJ Clin Lipidol20137539940724079280
   PubMed Web of Science ®Google Scholar
• JonesPHStatins: the case for higher, individualized starting dosesCleve Clin J Med200572981181616193828
   PubMed Web of Science ®Google Scholar
• McVeyDPatelHEmintonZMatonSAn assessment of the efficacy of atorvastatin in treating patients with dyslipidaemia to target LDL-cholesterol goals: the atorvastatin matrix studyInt J Clin Pract199953750951310692735
   PubMed Web of Science ®Google Scholar
• JonesPHMcKenneyJMKaralisDGDowneyJComparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemiaAm Heart J20051491e115660024
   PubMed Web of Science ®Google Scholar
• DucobuJClaeysMCommersKEfficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose studyCurr Med Res Opin20072381821182717609019
   PubMed Web of Science ®Google Scholar
• FarsangCAthyrosVGawAA multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST-2) studyCurr Med Res Opin20072381945195617626713
   PubMed Web of Science ®Google Scholar
• FoxKMGandhiSKOhsfeldtRLBlasettoJWDavidsonMHTitration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record databaseClin Ther200729112385239418158079
   PubMed Web of Science ®Google Scholar
• StargardtTThe impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in GermanyEur J Health Econ201011326727719639351
   PubMed Web of Science ®Google Scholar
• SakshaugSFuruKKarlstadORonningMSkurtveitSSwitching statins in Norway after new reimbursement policy: a nationwide prescription studyBr J Clin Pharmacol200764447648117441934
   PubMed Web of Science ®Google Scholar
• GizurarsonSBjornsdottirLREinarsdottirRHalldorssonMAndersenKClinical consequences following regulatory changes in respect to reimbursement of statins cost by the Icelandic Social Insurance AdministrationScand J Public Health201240766366723027893
   PubMed Web of Science ®Google Scholar
• TunceliKSajjanSGRameyDRSwitching from high-efficacy lipid-lowering therapies to simvastatin and low-density lipoprotein cholesterol goal attainment in coronary heart disease/coronary heart disease-equivalent patientsJ Clin Lipidol20104649150021122696
   PubMed Web of Science ®Google Scholar
• ManingatPGordonBRBreslowJLHow do we improve patient compliance and adherence to long-term statin therapy?Curr Atheroscler Rep201315129123225173
   PubMed Web of Science ®Google Scholar
• ConroyRMPyöräläKFitzgeraldAPSCORE project groupEstimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE projectEur Heart J20032411987100312788299
   PubMed Web of Science ®Google Scholar